文献速递脊柱关节炎

Guselkumab治疗TNF抑制剂应答不佳的活动性银屑病关节炎24周III期结果

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.
PubMed 文献 · Arthritis Rheumatol · 2026-04-16

SOLSTICE研究纳入对一种既往TNF抑制剂应答不佳的活动性银屑病关节炎成人患者451例,随机接受Guselkumab每4周、每8周或安慰剂治疗。24周时两种Guselkumab方案的ACR20、ACR50、ACR70、IGA 0/1、PASI90及MDA应答率均显著高于安慰剂(所有P<0.001)。安全性与已知特征一致。

要点

  • 对一种TNF抑制剂应答不佳的活动性PsA患者,Guselkumab 24周疗效显著优于安慰剂。
  • 两种给药方案(Q4W与Q8W)疗效相近,ACR20分别达58.6%和62.2%。
  • 安全性事件发生率与安慰剂相近,总体与已知安全性特征一致。

核心结论

  • 对一种既往TNF抑制剂应答不佳的活动性银屑病关节炎患者,Guselkumab在第24周显示出显著优于安慰剂的疗效。

研究设计与样本

  • SOLSTICE为IIIb期随机、多中心、双盲、安慰剂对照研究。
  • 纳入活动性PsA成人患者(肿胀关节≥3个、压痛关节≥3个、C反应蛋白≥0.3 mg/dL)且对一种既往TNF抑制剂应答不佳。
  • 随机分为Guselkumab 100 mg每4周、Guselkumab 100 mg第0和4周后每8周、或安慰剂(第24周转用Guselkumab每4周)组。
  • 分析纳入451例随机参与者(每4周组n=150;每8周组n=151;安慰剂组n=150)。

主要发现

  • 第24周,Guselkumab每4周/每8周组与安慰剂组分别有58.6%/62.2% vs 34.8%达到ACR20(主要终点)。
  • ACR50应答率分别为31.4%/32.1% vs 12.2%,ACR70为17.5%/17.3% vs 2.0%。
  • IGA 0/1应答率分别为50.0%/57.3% vs 17.4%,PASI90为49.4%/45.5% vs 12.0%,MDA为18.8%/23.9% vs 5.4%(所有P<0.001)。
  • 截至第24周,Guselkumab每4周组、每8周组和安慰剂组分别有46.7%、53.6%和48.3%的参与者发生至少一项不良事件。
  • 发生一例死亡(心肌梗死)。

关键数值与推荐

  • 主要终点:第24周ACR20应答率。
  • 次要终点包括ACR50、ACR70、IGA 0或1分且改善≥2级、PASI90、MDA,均按意向治疗分析。

临床怎么用

  • 对于一种TNF抑制剂应答不佳的活动性PsA患者,Guselkumab每4周或每8周方案均可考虑作为治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of guselkumab, an interleukin-23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor. METHODS: In SOLSTICE (phase 3b, randomized, multicenter, double-blind, placebo-controlled study), enrolled adults with active PsA (three or more swollen joints; three or more tender joints; C-reactive protein ≥ 0.3 mg/dL) and inadequate response to one prior TNF inhibitor were randomized to guselkumab 100 mg every 4 weeks (Q4W), guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo with crossover to guselkumab Q4W at week 24. The primary endpoint was ≥20% improvement in American College of Rheumatology criteria (ACR20) at week 24. Secondary endpoints included ACR50, ACR70, Investigator's Global Assessment of psoriasis (IGA) score of 0 or 1 with ≥2-grade improvement, ≥90% improvement in Psoriasis Area and Severity Index (PASI90), and minimal disease activity (MDA) at week 24 and were analyzed by intention-to-treat. RESULTS: Analyses included 451 randomized participants (Q4W n = 150; Q8W n = 151; placebo n = 150). At week 24, significantly greater proportions of guselkumab (Q4W/Q8W)-treated participants versus placebo-treated participants, respectively, achieved ACR20 (primary endpoint: 58.6%/62.2% vs 34.8%), ACR50 (31.4%/32.1% vs 12.2%), ACR70 (17.5%/17.3% vs 2.0%), IGA 0/1 response (50.0%/57.3% vs 17.4%), PASI90 (49.4%/45.5% vs 12.0%), and MDA (18.8%/23.9% vs 5.4%) (all P < 0.001). Through week 24, 46.7%, 53.6%, and 48.3% of participants receiving guselkumab Q4W, guselkumab Q8W, and placebo, respectively, had one or more adverse event. One death occurred (myocardial infarction). CONCLUSION: Comparable efficacy was observed with both guselkumab regimens in participants with active PsA and inadequate response to one prior TNF inhibitor; safety findings were consistent with the known profile of guselkumab in patients with psoriatic disease.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ogdie A, Merola JF, Mease PJ, et al. Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study. Arthritis Rheumatol. 2026. PMID: 41670439. doi:10.1002/art.70092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。